^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Dupert (fulzerasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRASG12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
Published date:
11/15/2022
Excerpt:
Favorable safety and tolerability and promising antitumor activity of IBI351 monotherapy were observed in previously-treated advanced NSCLC, CRC and pancreatic cancer harboring KRASG12C mutation.
Trial ID:
